Rxrx stock forecast.

NVIDIA Corporation Common Stock. $416.10 +5.93 +1.45%. ARM. Arm Holdings plc American Depositary Shares. $51.32 -0.84 -1.61%. Find the latest analyst research for Recursion Pharmaceuticals, Inc ...

Rxrx stock forecast. Things To Know About Rxrx stock forecast.

Jul 24, 2023 · As of July 24, 2023, 4:00 PM CST, Recursion Pharmaceuticals Inc’s stock price was $14.28. Recursion Pharmaceuticals Inc is down 7.69% from its previous closing price of $15.47. During the last market session, Recursion Pharmaceuticals Inc’s stock traded between $14.36 and $16.09. See Recursion Pharmaceuticals, Inc. (RXRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Nov 22, 2023 · The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target for the stock is $15.57, which implies that it could rise by about 120% over the next 12 months. Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Great weather can motivate you to get out of the house, while inclement weather can make you feel lethargic. When the weather’s great we want to be outside enjoying it. For the best regional weather forecasts check out AccuWeather.

Dec 1, 2023 · Company Summary. Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data ... Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.

Recursion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RXRX updated stock price target summary.Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...Current. -$0.35. 1 Month Ago. -$0.35. 3 Months Ago. -$0.32. Recursion Pharmaceuticals Inc. analyst estimates, including RXRX earnings per share estimates and analyst recommendations.8 авг. 2023 г. ... RXRX+0.08 (+1.17%) After Hours. Share Share Article via ... Global Business and Financial News, Stock Quotes, and Market Data and Analysis.Sep 11, 2023 · Recursion Pharmaceuticals (RXRX 7.88%) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug ...

Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

The exchange reported a loss of $2.43 per share, compared to forecasts of a $2.52 loss per share, according to the FactSet consensus. Revenue plummeted 75% to $629.1 million, but still beat ...

RXRX Stock Performance on July 28, 2023: Decrease in Price and Analyst Forecasts. RXRX stock performance on July 28, 2023, showed a decrease from the previous price. The 12-month price forecasts for Recursion Pharmaceuticals Inc provided by 8 analysts had a median target of 12.50, with a high estimate of 35.00 and a low estimate of 9.00.Average. $15.57. Current Price. $7.39. Options. Overview. Research & Ratings. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume ...Find real-time BLRX - BioLine RX Ltd stock quotes, company profile, news and forecasts from CNN Business.Oct 11, 2023 · On the bottom line, Recursion's net loss per share of $0.38 remained flat compared to the prior-year quarter. The company ended the period with $405.9 million in cash and equivalents, which does ... Should You Buy or Sell Recursion Pharmaceuticals Stock? Get The Latest RXRX Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.Recursion's stock soared 80% following the announcement. Shares of Nvidia, which have helped fuel stock market gains this year amid hopes about its AI computing chips , rose more than 2%.Recursion Pharmaceuticals (RXRX) stock price prediction is 10.137756245264 USD. The Recursion Pharmaceuticals stock forecast is 10.137756245264 USD for 2024 December 02, Monday; and 517.401 USD for 2028 December 02, Saturday with technical analysis.

As for revenue growth, note that RXRX's revenue has grown 65.02% over the past 12 months; that beats the revenue growth of 92.59% of US companies in our set. Stocks with similar financial metrics, market capitalization, and price volatility to RECURSION PHARMACEUTICALS INC are TSP, ALGS, FUSN, ITOS, and PRAX. RXRX's SEC …The Recursion Pharmaceuticals, Inc. stock price gained 7.88% on the last trading day (Friday, 1st Dec 2023), rising from $6.85 to $7.39. During the last trading day …What this means: Recursion Pharmaceuticals Inc Cl (RXRX) gets an Overall Rank of 60, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.RXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more.In the last three months, insiders have sold 333,493 shares of company stock worth $2,375,196. 19.96% of the stock is currently owned by insiders. Wall Street Analysts Forecast Growth

According to the current price, Recursion Pharmaceuticals, is 42.39% away from the 52-week high. What are analysts forecasts for Recursion Pharmaceuticals, stock? The 21 analysts offering price ...A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Analysts have provided the following ratings for Recursion Pharmaceuticals (NASDAQ:RXRX) within the last quarter: These 7 analysts have an average price target of $18.14 versus the current price ...The exchange reported a loss of $2.43 per share, compared to forecasts of a $2.52 loss per share, according to the FactSet consensus. Revenue plummeted 75% to $629.1 million, but still beat ...Recursion Pharmaceuticals (RXRX) stock price prediction is 10.137756245264 USD. The Recursion Pharmaceuticals stock forecast is 10.137756245264 USD for 2024 December 02, Monday; and 517.401 USD for 2028 December 02, Saturday with technical analysis. Track Recursion Pharmaceuticals Inc - Ordinary Shares - Class A (RXRX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsFind the latest Earnings Report Date for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at ... Read our earnings report guide before you consider the forecast information when making ...

Shares of Recursion Pharmaceuticals (RXRX 1.18%) ... Nvidia's stock was also up nearly 3%, but that may have had more to do with the inflation report that buoyed the market on Wednesday. In May ...

Both companies could tap into huge growth from the AI revolution in a few years. Schrödinger ( SDGR 2.90%) and Recursion Pharmaceuticals ( RXRX 4.40%) are both biotechs that want to use AI to ...

One thing we could say about the analysts on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - they aren't optimistic, having just made a major negative revision to their near-term (statutory ...According to our current RXRX stock forecast, the value of Recursion Pharmaceuticals, Inc. shares will drop by -9.72% and reach $ 6.59 per share by December 5, 2023. …Current. -$0.35. 1 Month Ago. -$0.35. 3 Months Ago. -$0.32. Recursion Pharmaceuticals Inc. analyst estimates, including RXRX earnings per share estimates and analyst recommendations.Recursion Pharmaceuticals Inc. research and ratings by Barron's. View RXRX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.The company raised guidance for annual organic revenue growth from an earlier forecast of between 5% and 7% to between 6% and 8%. It also raised annual adjusted EPS to be between $3.70 and $3.85 ...If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock quote, history, news and other vital information to help you with your stock trading and investing. The 7 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —. Analyst rating Based on 7 analysts giving stock ratings to RXRX in the past 3 months. Recursion's shares have rallied 191.5% in the past three months compared with the industry’s 0.1% growth. The steep rise in the stock price can also be attributed to RXRX’s recent ...Company Description. Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.Recursion Pharmaceuticals Inc Cl A stocks price quote with latest real-time prices, charts, financials, ... RXRX Related stocks. Symbol 3M %Chg ; RXRX -18.97% : Recursion Pharmaceuticals Inc Cl A: ZTS -6.96% : Zoetis Inc Cl A: TAK ... Cash Markets Overview Corn Indexes Soybean Indexes Yield Forecast Indexes.Dec 1, 2023 · Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.91) per share. Recursion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 26th, 2024 based off prior year's report dates. Read More.

12 июл. 2023 г. ... Recursion stock is up after Nvidia investment and collaboration. Time to buy RXRX Stock? or time to buy Nvidia Stock Price? A portion of ...Find the latest ARK Genomic Revolution ETF (ARKG) stock quote, history, news and other vital information to help you with your stock trading and investing.Heading out for an outdoor adventure? Whether you’re planning a picnic, a hiking trip, or a beach day, one essential tool you need in your arsenal is a detailed weather 10 day forecast.Instagram:https://instagram. .evrigoldman sachs creative planningiso20022 coindental insurance plans georgia Get free stock tools, free stock ratings, free stock charts and calculate the value of stocks to buy becoming a day tradercryptocurrency day trading course The latest price target for Recursion Pharmaceuticals ( NASDAQ: RXRX) was reported by JP Morgan on Monday, November 13, 2023. The analyst firm set a price target for 10.00 expecting RXRX to rise ...Investors looking for stocks that can put up dramatic gains ... (RXRX 7. 88%) have fallen by ... Zynteglo's U.S. launch will be extra difficult to forecast because its strategy involves returning ... tyson transportation Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Are you tired of spending countless hours manually tracking your inventory? Are you looking for a way to improve your decision making and forecasting processes? Look no further than a free inventory tracking template.Nov 22, 2023 · The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target for the stock is $15.57, which implies that it could rise by about 120% over the next 12 months.